Viva Biotech Holdings and BioMap Platform Reach a Collaboration

BioMap and Adock is the first generation of the China Biocomputing Conference, which was launched in Suzhou. The conference focuses on uniting biotech and IT industry partners to create a multi-party integrated industrial ecosystem and realize AI’s comprehensive empowerment in the field of biotechnology.

China-based investment holding was invited to attend the conference and announced a strategic collaboration agreement with BioMap. This collaboration will be based on the AI + biological computing engine from BioMap, with the structure-based drug discovery platform from Viva Biotech, to jointly accelerate the R & D of the novel drugs.

Dr Delin Ren, President of Viva Biotech, said that the integration of AI deep learning technology and SBDD technology platform is bound to have a far-reaching impact on drug design and R & D. This collaboration between Viva Biotech and BioMap is the perfect combination of these two technologies. It is expected to shorten the R & D cycle and improve the success rate of novel drug discovery.

Liu Wei, the co-founder and CEO of BioMap said that high tech biological data is the basis of biocomputing platform development. Viva Biotech has the world’s leading protein structure analysis technology and capabilities. The collaboration with Viva Biotech will help BioMap to obtain high-quality macromolecular structure data, especially those of new targets, artificially designed antibody molecules, and target-drug complexes in a high-throughput manner. Combined with the powerful computing power and algorithm development capabilities of BioMap, the collaboration is expected to accelerate the development of BioMap’s AI macromolecular drug platform, which would eventually contribute to new drug development.

AlxplorerBio and EPN, two biotech companies that were invested and incubated by Viva BioInnovator, also attended this meeting and signed the collaboration agreement. As of December 31, 2020, Viva Biotech had provided drug discovery and production services to 1,252 pharmaceutical clients worldwide, worked on over 1,500 independent drug targets, delivered approximately over 21,000 independent protein structures and incubated/invested 67 biotech companies.